Oncogenic role of MIR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

Journal of Pathology

Volumn 236, Issue 4, 2015, Pages 445-456

  Merkel, Olaf ^a,c,g   Hamacher, Frank ^b   Griessl, Robert ^b   Grabner, Lisa ^c   Schiefer, Ana Iris ^c   Prutsch, Nicole ^c   Baer, Constance ^a   Egger, Gerda ^c,g   Schlederer, Michaela ^c,e   Krenn, Peter William ^b   Hartmann, Tanja Nicole ^b   Simonitsch Klupp, Ingrid ^c   Plass, Christoph ^a   Staber, Philipp Bernhard ^c   Moriggl, Richard ^e,f   Turner, Suzanne D ^d,g   Greil, Richard ^b   Kenner, Lukas ^c,e,f,g  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^g European Research Initiative on ALK Related Malignancies   (Australia)

Author keywords

ALCL; ALK kinase; cytokines; IL 10; IL 21; IL 22; miR 155

Indexed keywords

ARGONAUTE 2 PROTEIN; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN BETA; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 8; MICRORNA 155; NUCLEOPHOSMIN; NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA TYROSINE KINASE FUSION PROTEIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; ARGONAUTE PROTEIN; CASP3 PROTEIN, HUMAN; CEBPB PROTEIN, HUMAN; EIF2C2 PROTEIN, HUMAN; MICRORNA; MIRN155 MICRORNA, HUMAN; SOCS1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA METHYLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LARGE CELL LYMPHOMA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA METHYLATION; SIGNAL TRANSDUCTION; TUMOR ENGRAFTMENT; WESTERN BLOTTING; ANIMAL; CASE CONTROL STUDY; CHROMOSOME 2; CHROMOSOME 5; DEFICIENCY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSLOCATION; GENETIC TRANSFECTION; GENETICS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; PROMOTER REGION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ARGONAUTE PROTEINS; CASE-CONTROL STUDIES; CASPASE 3; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE, INBRED NOD; MICE, SCID; MICRORNAS; PROMOTER REGIONS, GENETIC; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION; TRANSLOCATION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937515806     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4539     Document Type: Article

References (48)

1. Chiarle R, Voena C, Ambrogio C, et al., The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
2. Inghirami G, Pileri SA,. Anaplastic large-cell lymphoma. Semin Diagn Pathol 2011; 28: 190-201.
3. Vega F, Medeiros LJ, Leventaki V, et al., Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006; 66: 6589-6597.
4. + anaplastic large-cell lymphoma. Blood 2006; 108: 2796-2803.
5. Chiarle R, Simmons WJ, Cai H, et al., Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629.
6. Watanabe M, Sasaki M, Itoh K, et al., JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. Cancer Res 2005; 65: 7628-7634.
7. Yamamoto R, Nishikori M, Tashima M, et al., B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009; 100: 2093-2100.
8. Turner SD, Yeung D, Hadfield K, et al., The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 2007; 19: 740-747.
9. Laimer D, Dolznig H, Kollmann K, et al., PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18: 1699-1704.
10. Bai RY, Dieter P, Peschel C, et al., Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase Cγ to mediate its mitogenicity. MolCell Biol 1998; 18: 6951-6961.
11. Wellmann A, Doseeva V, Butscher W, et al., The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J 1997; 11: 965-972.
12. Ambrogio C, Voena C, Manazza AD, et al., p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 2005; 106: 3907-3916.
13. Kuefer MU, Look AT, Pulford K, et al., Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901-2910.
14. Lange K, Uckert W, Blankenstein T, et al., Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 2003; 22: 517-527.
15. Chiarle R, Gong JZ, Guasparri I, et al., NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101: 1919-1927.
16. Turner SD, Merz H, Yeung D, et al., CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 2006; 26: 3275-3279.
17. Turner SD, Tooze R, Maclennan K, et al., Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003; 22: 7750-7761.
18. + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.
19. Eckerle S, Brune V, Doring C, et al., Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23: 2129-2138.
20. + subtypes. Blood 2007; 109: 2156-2164.
21. Piva R, Pellegrino E, Mattioli M, et al., Functional validation of the anaplastic lymphoma kinase signature identifies CEBPβ and BCL2A1 as critical target genes. J Clin Invest 2006; 116: 3171-3182.
22. Piva R, Pellegrino E, Inghirami G,. Identification and validation of the anaplastic large cell lymphoma signature. Adv Exp Med Biol 2007; 604: 129-136.
23. Swerdlow SH, Harris NL, Campo E, et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon, France, 2008.
24. Feldman AL, Dogan A, Smith DI, et al., Discovery of recurrent t(6;7) (p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117: 915-919.
25. Cui YX, Kerby A, McDuff FK, et al., NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 2009; 113: 5217-5227.
26. Boi M, Rinaldi A, Kwee I, et al., PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 2013; 122: 2683-2693.
27. Iqbal J, Wright G, Wang C, et al., Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915-2923.
28. - anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010; 107: 16228-16233.
29. Mehrotra M, Medeiros LJ, Luthra R, et al., Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol 2014; 45: 1995-2005.
30. Spaccarotella E, Pellegrino E, Ferracin M, et al., STAT3-mediated activation of microRNA cluster 17-92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica 2013; 99: 116-124.
31. O'Connell RM, Rao DS, Chaudhuri AA, et al., Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-594.
32. Costinean S, Zanesi N, Pekarsky Y, et al., Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-7029.
33. Meier J, Hovestadt V, Zapatka M, et al., Genome-wide identification of translationally inhibited and degraded MIR-155 targets using RNA-interacting protein-IP. RNA Biol 2013; 10: 1018-1029.
34. Baer C, Claus R, Frenzel LP, et al., Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res 2012; 72: 3775-3785.
35. Bosma GC, Owen J, Easton G, et al., Concentration of IgG1 and IgG2a allotypes in serum of nude and normal allotype-congenic mice. J Immunol 1980; 124: 879-884.
36. Schlederer M, Mueller KM, Haybaeck J, et al., Reliable quantification of protein expression and cellular localization in histological sections. PloS One 2014; 9: e100822.
37. O'Connell RM, Rao DS, Chaudhuri AA, et al., Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10: 111-122.
38. + anaplastic large cell lymphoma. Leukemia 2008; 22: 1595-1603.
39. Dien Bard J, Gelebart P, Anand M, et al., IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 2009; 175: 825-834.
40. Escobar TM, Kanellopoulou C, Kugler DG, et al., MIR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity 2014; 40: 865-879.
41. Glasmacher E, Agrawal S, Chang AB, et al., A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 2012; 338: 975-980.
42. Bluml S, Bonelli M, Niederreiter B, et al., Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthrit Rheum 2011; 63: 1281-1288.
43. Thai TH, Calado DP, Casola S, et al., Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608.
44. Sabat R, Ouyang W, Wolk K,. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014; 13: 21-38.
45. Sanda T, Tyner JW, Gutierrez A, et al., TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013; 3: 564-577.
46. Kiel MJ, Velusamy T, Rolland D, et al., Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014; 124: 1460-1472.
47. Liang J, Tsui V, Van Abbema A, et al., Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 2013; 67: 175-187.
48. Sohn SJ, Barrett K, Van Abbema A, et al., A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013; 191: 2205-2216.